Kenya will begin producing a new monthly HIV prevention pill under a royalty-free license, marking a significant step in global health efforts. The drug, developed by a leading pharmaceutical company, will be manufactured by Universal Corporation, a Kenyan firm known for its pharmaceutical expertise. This initiative aims to increase access to preventive treatments in low- and middle-income countries, where HIV remains a major public health challenge.
The production is expected to start in 2025, with the goal of supplying the medication to 129 countries. This move comes as part of a broader strategy to combat HIV through prevention and treatment. Kenya’s involvement highlights its growing role in global health innovation, leveraging local manufacturing capabilities to address international health needs.
The new pill offers a monthly dose, making it more convenient for users compared to daily regimens. This could improve adherence and reduce the burden on healthcare systems. The project also underscores Kenya’s commitment to contributing to global health equity, aligning with international goals to end the HIV epidemic by 2030.
